[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616231":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":38,"responsibleParty":84,"collaborators":11,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":88,"sex":94,"minAge":95,"maxAge":11,"enrollmentInfo":96,"targetDuration":11,"studyType":99,"phases":100,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":41,"whyStopped":11,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental Arm","EXPERIMENTAL",null,[13],"Combination Product: DEB-DoxNic-TACE",{"label":15,"type":16,"description":11,"interventionNames":17},"Control Arm","ACTIVE_COMPARATOR",[18],"Combination Product: current standard of care",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"COMBINATION_PRODUCT","DEB-DoxNic-TACE","TACE (transarterial chemoembolization) with 1-3 mL drug-eluting beads (DEB) loaded with 33mg\u002Fml doxorubicin (Dox) and 0.3mg\u002FmL nicardipine (Nic)",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"current standard of care","TACE (transarterial chemoembolization) with 1-3 mL drug-eluting beads loaded with 33mg\u002Fml doxorubicin",[15],[30],{"name":31,"affiliation":5,"role":32},"Fahim Ebrahimi, PD Dr.","STUDY_DIRECTOR",[34],{"name":31,"role":35,"phone":36,"phoneExt":11,"email":37},"CONTACT","+41 61 777 74 00","fahim.ebrahimi@clarunis.ch",[39,58,71],{"facility":40,"status":41,"city":42,"state":11,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"University Hospital Basel","RECRUITING","Basel","4031","Switzerland","CH",{"type":47,"coordinates":48},"Point",[49,50],7.57327,47.55839,{"lat":50,"lon":49},[53,55],{"name":31,"role":35,"phone":54,"phoneExt":11,"email":37},"+41 61 777 74 38",{"name":56,"role":57,"phone":11,"phoneExt":11,"email":11},"Markus Heim, Prof.","PRINCIPAL_INVESTIGATOR",{"facility":59,"status":41,"city":60,"state":11,"zip":61,"country":44,"countryCode":45,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Hôpitaux Universitaires de Genève","Geneva","1205",{"type":47,"coordinates":63},[64,65],6.14569,46.20222,{"lat":65,"lon":64},[68,70],{"name":69,"role":35,"phone":11,"phoneExt":11,"email":11},"Nicolas Goossens, PD Dr.",{"name":69,"role":57,"phone":11,"phoneExt":11,"email":11},{"facility":72,"status":41,"city":73,"state":11,"zip":74,"country":44,"countryCode":45,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Kantonsspital St. Gallen","Sankt Gallen","9007",{"type":47,"coordinates":76},[77,78],9.37477,47.42391,{"lat":78,"lon":77},[81,83],{"name":82,"role":35,"phone":11,"phoneExt":11,"email":11},"David Semela, PD Dr.",{"name":82,"role":57,"phone":11,"phoneExt":11,"email":11},{"type":85,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100616231","phase-2-transarterial-chemoembolization-tace-plus-abcb1-inhibition-versus-tace-alone-in-patients-with-hepatocellular-carcinoma-100616231",false,"NCT07302919","Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma","Randomized, Double-Blind, Parallel, Controlled, Multicenter Study of Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma: IMPACT-TACE","IMPACT-TACE","Inclusion Criteria:\n\n* Informed consent as documented by signature,\n* Age ≥18 years,\n* Diagnosis of HCC by biopsy or by established imaging criteria using CT or MRI,\n* At least one target lesion without prior treatment,\n* Diameter of the target lesion ≥3 cm and ≤8 cm,\n* Preserved liver function (no jaundice, no ascites, no overt hepatic encephalopathy).\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods for at least 3 months after the TACE treatment.\n\nExclusion Criteria:\n\n* Any prior systemic therapy for advanced HCC,\n* Diffuse tumor lesions, extrahepatic metastases, or vascular invasion,\n* Hepatic encephalopathy,\n* Uncontrolled ascites or pleural effusion,\n* Jaundice,\n* Severe hypotension or hemodynamic shock or need of vasoactive medications,\n* Decompensated heart failure New York Heart Association (NYHA) class IV,\n* eGFR \\\u003C 15 mL\u002Fmin\u002F1.73 m2 per MDRD (Modification of Diet in Renal Disease) formula,\n* Myocardial infarction within the last 6 months,\n* Life expectancy \\\u003C12 weeks,\n* Contraindications to the class of drugs under study, e.g., known hypersensitivity or allergy to calcium antagonists,\n* Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant,\n* Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within at least 3 months after the TACE treatment.","ALL","18 Years",{"count":97,"type":98},152,"ESTIMATED","INTERVENTIONAL",[101,102],"PHASE2","PHASE3","IMPACT-TACE is an investigator-initiated, prospective, multicenter, randomized, double-blinded, interventional trial to test the hypothesis that the simultaneous application of doxorubicin with the ABCB1 inhibitor nicardipine would significantly improve the success rate of TACE treatment.",[105],"Hepato Cellular Carcinoma (HCC)",[107],"Transarterial Chemoembolization (TACE)","2026-02-26",{"date":110,"type":111},"2026-03-02","ACTUAL",{"date":113,"type":111},"2026-02-16",{"date":115,"type":98},"2028-06",{"name":5,"class":6},3]